Further evidence from Lilly (the makers of Zyprexa) on the adverse effects of antipsychotic medications in the elderly from the Journal of Clinial Psychiatry . Six studies were examined for mortality , CVAEs and other adverse effects in the use of olanzapine, risperidone and conventional anti-psychotics . Mortality was found to be significantly higher in olanzapine treated patients (3.5%)than in placebo treated patients ( 1.5%) There was no difference in crude mortality between olanzapine and risperidone and conventional anti-psychotics.
A Review of Treatment-Emergent Adverse Events During Olanzapine Clinical Trials in Elderly Patients With Dementia.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment